Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2006

View Archived Issues

Genta and Emisphere sign licensing agreement for oral gallium compound

Enrollment completed in phase II solid tumor study of CA4P with chemotherapy

Grip strength measurements improve in BioAstin tendonitis study

Noxxon and Pfizer form Spiegelmer product alliance

Pharming to acquire DNage

Reata advances RTA-402 into clinical testing

Paion begins program for next-generation plasminogen activators

Mimetogen completes Series A financing, new licensing agreement

Bioaccelerate Holdings to change name, spin off subsidiaries

Positive opinion handed down in Europe for Ganfort

Exenatide LAR studied for type 2 diabetes in new study

Opposing trends in Oncophage renal cancer phase III trial

CHMP recommends against approval of Zelnorm for IBS-C in Europe

Phase II data for ALGRX-4975 in hernia repair at odds with other phase II results

New dosages of Risperdal M-TAB now available

Rectogesic completes E.U. mutual recognition procedure

Novel calcium-sensing receptor antagonist promotes PTH release in vivo

Affibody molecules -- a tool for preclinical drug profiling

Inhibitors of 11beta-HSD1: candidates for the treatment of obesity, diabetes and metabolic syndrome

Lyrica receives European approval for GAD

Aranesp approved for every-three-week dosing

New treatment options for cancer covered in recent patents

Cubist responds to approvable letter for Cubicin

Data on new chemokine CXC receptor antagonists reported at ACS meeting

Preclinical data on the antidiabetic compound SYR-322 presented

A novel target to improve memory: ghrelin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...